The US Center for Medicare and Medicaid Innovation’s plan to reduce drug costs by giving Medicare Part D beneficiaries access to select generic drugs for up to $2 a month did not receive a warm reception from the generic industry, largely because it is seen as focusing on drugs that are already firmly entrenched and not incentivizing better coverage of newer follow-on products.
For Generic Manufactures, New Medicare Drug Pricing Demo Is a Dud
The proposed CMS innovation center's $2 drug list model will not address the barriers to newer generics getting on Part D formularies and plans may have little incentive to participate in the demo, an industry group said.
More from Drug Pricing
More from Generics Bulletin
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
Echoing wider sentiments in the biosimilar and generic drug industry, the IGBA has warned of the potential consequences of mercantilist tariffs on the global drug supply and their impact on industry and patients.